What South Lake Compounding does not publish
As of June 2026, slcompounding.com does not disclose the names of ownership or leadership, corporate structure, funding or investor history, or specific state-by-state shipping licensure details. Per-vial pricing and clinic agreement terms are not posted publicly. The specific scope of any controlled substance compounding program and detailed formulary pricing are discussed after physician enrollment. The site also does not publish patient volume, order counts, or how many clinics are enrolled.
None of these gaps are unusual for a privately held compounding pharmacy. The typical due diligence path is direct: request the state pharmacy licensure and any accreditation documentation from South Lake directly, ask for references from similarly sized clinics, and review the clinic agreement terms before signing. The publicly verifiable compliance signals — USP <797>/<800>, FDA-registered raw materials, third-party lab testing — are meaningful indicators of compounding quality even without corporate disclosures.